Smad proteins are crucial for the intracellular signaling of transforming growth factor-b (TGF-b). Upon their receptor-induced activation, Smad proteins are phosphorylated and translocated to the nucleus to activate the transcription of a select set of target genes. Here, we show that the co-activator p300/CBP bound and acetylated Smad3 as well as Smad2 in vivo, and that the acetylation was stimulated by TGF-b. A major acetylation site of Smad3 by p300/CBP is Lys-378 in the MH2 domain (Smad3C) known to be critical for the regulation of transcriptional activity. Replacement of Lys-378 with Arg decreased the transcriptional activity of GAL4-Smad3C in a luciferase assay. Moreover, p300/CBP potentiated the transcriptional activity of GAL4-Smad3C, but not the acetylation-resistant GAL4-Smad3C(K378R) mutant. These results suggest that acetylation of Smad3 by p300/CBP regulates positively its transcriptional activity.
Introduction
Members of the transforming growth factor-b (TGF-b) superfamily are critical regulators for tissue development and homeostasis, including proliferation, differentiation, migration and apoptosis, in metazoan organisms . TGF-b and related factors bind to two different types of serine/threonine kinase receptors, termed type I and type II. Type II receptor kinases are constitutively active; upon binding a ligand and forming a complex with type I receptors, type II receptors phosphorylate type I receptors, resulting in the phosphorylation and activation of Smads by the type I receptor kinases Massague´and Wotton, 2000) . One class of Smads, the receptor-regulated Smads (R-Smads), are directly phosphorylated at the C-terminal SSXS motif by type I receptors. This induces binding of the R-Smad to the common Smad (Co-Smad) Souchelnytskyi et al., 1997) . The R-Smad/Co-Smad complexes are then translocated into the nucleus, where they bind to transcriptional co-activators or corepressors and regulate transcription (Attisano and Wrana, 2000; Miyazono, 2000) . A third class of Smads, the inhibitory Smads, interfere with the activation of R-Smads by the activated type I receptors and the formation of R-Smad/Co-Smad complexes Imamura et al., 1997; Nakao et al., 1997) . Smad2 and -3 are R-Smads activated by TGF-b and activin receptors, whereas Smad1, -5 and -8 are activated by BMP receptors. In the nucleus, the Smad oligomers recruit the transcriptional co-activators p300/ CBP (Feng et al., 1998; Janknecht et al., 1998; Nishihara et al., 1998; Itoh et al., 2000) . p300 and CBP are structurally related proteins with histone acetyltransferase (HAT) activity.
Acetylation is a post-translational modification of proteins, with histones being the best-known example (Hasan and Hottiger, 2002; Freiman and Tjian, 2003) . Several enzymes are reported to be HATs, including p300/CBP, p300/CBP-associated factor (PCAF), SRC1 and MOZ. Recently, these acetyltransferases have been shown to modify other proteins besides histones, including general transcription factors such as p53, E2F-1, GATA-1 and MyoD. The functional consequences of acetylation are diverse and include increased DNA binding (p53, GATA-1 and MyoD) (Gu and Roeder, 1997; Boyes et al., 1998; Sartorelli et al., 1999) , decreased DNA binding, increased stability (E2F-1) (Martinez-Balbas et al., 2000) , inhibition of nuclear export and changes in protein-protein interactions.
In this report, we demonstrate that Smad3 is a direct target of the transcriptional co-activators p300/CBP, and this acetylation is stimulated by TGF-b. The acetylation of Smad3 induced by p300/CBP occurs in the MH2 domain, which is known to be critical for the transcriptional activity. Lysine residue 378 in the MH2 domain is one of the targets in p300-mediated acetylation. p300 potentiated the transcriptional activity of heterologous GAL4-Smad3MH2 fusion proteins, but not the acetylation-resistant GAL4-Smad3MH2 mutant. These results suggest that acetylation of Smad3 by p300/CBP regulates the transcriptional activity of Smad3.
Results

p300/CBP acetylates Smad2 and -3
The transcriptional co-activators p300/CBP have been shown to interact in a ligand-dependent manner with R-Smads. The fact that Smad3 interacted with p300/ CBP suggested that it could be a substrate for the acetyltransferase activity of p300/CBP. In order to test this possibility, 293 cells were transfected with FlagSmad3 alone or together with p300, or CBP, and the immunoprecipitate was immunoblotted with the antiacetylated lysine antiserum. p300 or CBP induced a robust acetylation of Smad3 (Figure 1a, lanes 3 and 4) ; however, Smad3 was slightly acetylated when it was expressed alone ( Figure 1a, lane 2) . Acetylation of Smad2 by p300 was also observed (Figure 1b) . As shown in Figure 1c , p300 and CBP were also able to acetylate p53, confirming their activity toward other substrates. Acetylated Smad3 was readily detected with the co-expression of wild-type CBP but not with an HAT-deficient mutant of CBP (CBP-DHAT) (Figure 1e , lanes 3 and 4), indicating that acetylation of Smad3 required the enzymatic activity of p300/CBP. Acetylation of Smad2 and -3 was slightly detectable without ectopic expression of p300/CBP, possibly owing to the Smad3 is acetylated to activate by p300/CBP Y Inoue et al limited amount of endogenous p300/CBP activity. Moreover, acetylation of recombinant GST-Smad3 was detected by immunoprecipitated p300, CBP or PCAF, transfected in 293 T cells (data not shown).
TGF-b enhances acetylation of Smad2 and -3 Next, we investigated whether the acetylation of Smad3 is regulated by TGF-b. The 293 cells were transfected transiently with Flag-Smad3 and p300 in either the presence or absence of a constitutively active form of the TGF-b type I receptor, TbRI(T204D)-HA. The acetylation of Smad3 was observed without TGF-b stimulation; however, activation of the TGF-b receptor dramatically enhanced its acetylation by p300 (Figure 2a, lanes 3 and 4) . Similar result was observed when ectopic Smad2 was expressed in 293 cells (data not shown).
To determine whether endogenous Smad2/3 are acetylated in response to TGF-b, we used anti-Smad2/ 3 antibodies to immunoprecipitate Smad2/3 from HepG2 cell lysates. We tried to observe the acetylation of endogenous Smad3, but Western blot analysis indicates that intracellular levels of Smad3 are very low, and that anti-Smad2/3 antibodies have less affinity for Smad3 than Smad2. For these reasons, we observed the acetylation of endogenous Smad2 instead of endogenous Smad3. As shown in Figure 2b , Smad2 was little acetylated in the steady state, but treatment with TGF-b enhanced the acetylation of endogenous Smad2 in the presence or absence of trichostatin A (TSA). We also tested another cell line A375, which is also responsive to TGF-b. As shown in Figure 2c , a high level of acetylated Smad2 was detected in response to TGF-b. These results show that Smad2 is acetylated in response to TGF-b in vivo.
Phosphorylation of Smad2/3 is preceded from and necessary for their acetylation Next, we investigated the expression of phosphorylated Smad2 and acetylated Smad2 in response to TGF-b using HepG2 cells (Figure 3a ). The phosphorylation of Smad2 peaked at 30 min and was sustained for 2 h. In contrast, the acetylation of Smad2 was delayed compared to the phosphorylation, although it reached a peak at 2 h. In the presence of TSA, the phosphorylation and acetylation of Smad2 were not changed. We also used a novel synthetic compound, SB431542, which has been shown to inhibit specifically activin receptor-like kinase (ALK)-4/5 (TbRI)/7 kinase activity, but not affect ALK-2/3/6 kinase activity Inman et al., 2002) . As shown in Figure 3b , SB431542 inhibited the acetylation of Smad2 as well as the phosphorylation induced by TGF-b. Taken together, these results speculate that Smad2 is phosphorylated in response to TGF-b and translocated into the nucleus, where it is acetylated.
Receptor activation results in phosphorylation of the two distal serines in the carboxy-terminal SSXS sequence of Smad3 Souchelnytskyi et al., 1997) . Replacement of the three serines with alanines (Smad3(3SA)) renders Smad3 biologically inactive, perhaps owing to an impaired release from the receptor, lack of heteromerization with Smad4 and/or an inability to translocate into the nucleus. We investigated whether Smad3(3SA) is acetylated by p300 in the presence or absence of TbRI(T204D)-HA. Little acetylation of Smad3(3SA) by p300 was observed, and activation of the TGF-b receptor did not enhance the acetylation (Figure 3c , lanes 4 and 5).
Lysine residue 378 in Smad3 is targeted by p300-mediated acetylation Previous reports showed that Smad3 interacts with p300/CBP through its MH2 region (Feng et al., 1998; Janknecht et al., 1998; Nishihara et al., 1998) . We Smad3 is acetylated to activate by p300/CBP Y Inoue et al therefore prepared the deletion mutants of Smad3 (Figure 4a ), and performed an acetylation assay. Smad3LC, which has the MH2 and linker regions, or Smad3C, which has only the MH2 region, were acetylated similar to the full-length form of Smad3 ( Figure 4b , lanes 2, 3 and 5). In contrast, Smad3N and Smad3NL, which have MH1 region or the MH1 and linker regions, respectively, were not acetylated ( Figure 4c , lanes 2 and 3). These results suggest that p300 binds to the MH2 region and acetylates Smad3. There are four lysine residues in the MH2 domain of Smad3, namely K333, K341, K378 and K409. To identify the lysine(s) of the MH2 domain acetylated by p300, we performed site-directed mutagenesis using the Flag-Smad3LC expression plasmid to change the four single lysines to arginine residues, and performed an acetylation assay (Figure 5a ). Interestingly, acetylation of Smad3LC(K378R) by p300 was significantly decreased (lane 5). Mutation of all four lysines The 293 cells were transiently transfected with the expression plasmids for Smad3 or its deletion mutants with pCMVb/p300. Cells were incubated with TSA (5 mM) for 18 h. Cell lysates were analysed as described in Figure 1a . Smad3 is acetylated to activate by p300/CBP Y Inoue et al (4KR) prevented acetylation of Smad3LC (lane 7). This lack of acetylation could not be explained by effects on the interaction between Smad3 and p300, as Smad3LC(K378R) and Smad3LC(4KR) still interacted with p300 in vivo (Figure 5b ). The reduction of acetylation in K378R mutant is also observed in fulllength Smad3 (Figure 5c ). These results suggest that K378 in the MH2 region of Smad3 is the main site of acetylation by p300 in vivo.
Acetylation regulates the transcriptional activity of Smad3
The MH2 domain of the Smad proteins exhibits a transactivation function through heterologous fusion with the GAL4 DNA-binding domain, suggesting that Smads may directly associate with the basal transcriptional machinery (Wu et al., 1997) . We therefore evaluated the effect of Smad3 acetylation on the function of Smad3 as a transactivator. We transiently transfected HepG2 cells with GAL4-Smad3 and assessed the transcriptional activity of Smad3 using a luciferase reporter assay. As shown in Figure 6a , TGF-b augmented the activity of GAL4-Smad3 by 7.0-fold. GAL4-Smad3C, which has only the MH2 domain, had stronger activity (16.7-fold) than the wild type, consistent with a previous report (Wu et al., 1997) . However, mutation of K378 (GAL4-Smad3C(K378R)) and mutation of all four lysines (GAL4-Smad3C(4KR)) significantly decreased the transcriptional activity (85 and 97% reduction, respectively). Moreover, p300
Figure 5 Lysine residue 378 in Smad3 is one of the targets in p300-mediated acetylation. (a) The 293 cells were transiently transfected with the wild-type or KÀ>R mutants of Smad3LC expression plasmids with pCMVb/p300. Cells were incubated in the presence of TSA (5 mM) for 18 h. Cell lysates were analysed as described in Figure 1a . (b) The 293 cells were transiently transfected with the wild-type or KÀ>R mutants of Smad3LC expression plasmids with pCMVb/p300. Cell lysates were immunoprecipitated (IP) with anti-Flag antibody, and the presence of p300 in each immunoprecipitate was evaluated by immunoblotting (Blot) with anti-p300 antibody (top). The same Western blot filter was probed with antiFlag antibody to estimate the immunoprecipitation efficiency and Flag-Smad3LC expression (middle). The expression level of each protein was assessed by direct immunoblotting of cell lysates with anti-p300 antibody (bottom). (c) The 293 cells were transiently transfected with wild-type or K378R mutant of Smad3 expression plasmids with pCMVb/p300. Cells were incubated in the presence of 5 mM of TSA for 18 h. Cell lysates were analysed as described in Figure 1a . Figure 6 Lysine 378 in Smad3 is critical for the p300-stimulating transcriptional activity of Smad3. (a) HepG2 cells were cotransfected with 5 Â GAL4-Luc reporter gene, GAL4-Smad3 and pCMV-bgal and treated with or without TGF-b. The luciferase activity in cell lysates was measured and was normalized with bgal activity. (b) HepG2 cells were co-transfected with 5 Â GAL4-Luc reporter gene, GAL4-Smad3 and pRL-TK in the absence or presence of p300. The luciferase activity in cell lysates was measured and was normalized with Renilla luciferase activity.
Smad3 is acetylated to activate by p300/CBP Y Inoue et al increased the transcriptional activity of GAL4-Smad3C(wt), but not that of GAL4-Smad3C(K378R) (Figure 6b ). The acetylated K378 residue was replaced with glutamine (K378Q) to create an acetylation mimic. The transcriptional activity of GAL4-Smad3C(K378Q) was greater than that of GAL4-Smad3C(wt), and was not increased by p300 (Figure 6b ). Taken together, these results suggest that acetylation increases the activation potential of Smad3. Consistent with these results, Smad3 K378R mutant decreased the transactivation of TGF-b-responsive promoter, such as p3TP-Lux-and Smad7-promotercontaining reporter gene (Figure 7a and b) . We have also observed the suppression effect of K378R mutant on the induction of several TGF-b target genes, plasminogen activator inhibitor-1 (PAI-1), Smad7 and COL1A2, in the transiently transfected 293 cells by reverse transcriptase-polymerase chain reaction (RT-PCR) methods (Figure 7c ).
Discussion
In this study, we have shown the acetylation of Smad3 by p300/CBP in response to TGF-b. Based on this finding, we propose a mechanism for the regulation of Smad3 by TGF-b. TGF-b binds to TGF-b receptors and phosphorylates Smad2/3 through type I receptors, which induces the binding of Smad2/3 to Smad4. The Smad2/3-Smad4 heterotrimer is then translocated into the nucleus where it binds to the transcriptional co-activators p300/CBP. Smad3 is acetylated by p300/ CBP and this modification stimulates the transactivation activity of Smad3.
We identified K378 in the MH2 domain of Smad3 as a major target for acetylation by p300/CBP. K378 resides in the conserved L3 loop of Smad3, which is known to participate in recognition of the L45 loop in the TGF-b type I receptor Wu et al., 2001) . K378 is fully conserved among all Smads and among all members of this family in various species. The MH2 domain of the Smad proteins exhibits a transactivation function through heterologous fusion with the GAL4 DNA-binding domain (Wu et al., 1997) . We therefore evaluated the effect of the Smad3 acetylation of Smad3 on its function as a transactivator (Figure 6 ). GAL4-Smad3C has a high level of constitutive transcriptional activity in a ligand-independent manner. But the acetylation-resistant GAL4-Smad3C mutant (GAL4-Smad3C(K378R)) had significantly decreased transcriptional activity and was unresponsive to p300. These The luciferase activity in cell lysates was measured and was normalized with bgal activity. (c) The 293 cells were co-transfected with Smad3 expression plasmids and pCMV5/TbRI(T204D). After 40 h, total RNA samples isolated from these cells were subjected to RT-PCR analysis. RT-PCR products were separated on 1.5-2% agarose gel. The expression levels of transfected Smad3 and TbRI(T204D) were shown at the bottom.
Smad3 is acetylated to activate by p300/CBP Y Inoue et al results suggest that acetylation of Smad3 by p300/CBP potentiates the transactivation activity of Smad3.
We also compared the transcriptional activity of wildtype Smad3 with that of the Smad3K378R mutant by conducting a luciferase assay using a TGF-b-responsive promoter-reporter construct, p3TP-Lux and pSmad7-Luc. The K378R mutant, as well as 4KR mutant, had less transcriptional activity than wild-type Smad3, consistent with Figure 6a . The Smad3K378R mutant was phosphorylated less than the wild type, because Smad3K378R could interact with type I receptor, TbRI, but not easily dissociate from it effectively (data not shown). Therefore, we could not conclude that the decreased transcriptional activity of Smad3K378R mutant was owing to a lack of acetylation of K378. However, GAL4-Smad3C(wt) and GAL4-Smad3C(K378R) are tethered to DNA by a heterologous DNA-binding domain, GAL4DBD, in a ligand-independent manner. Therefore, we speculate that GAL4-Smad3C(K378R) had significantly decreased transcriptional activity and was unresponsive to p300, indicating that this mutant is resistant to acetylation and transcriptional activation by p300/CBP.
In Figure 2 , TSA did not upregulate the p300-induced acetylation of Smad2. Acetylation level of Smad2 (probably also Smad3) depends on the balance between HAT and histone deacetylase (HDAC) activities. Upon TGF-b stimulation, HDACs associated with Smad2/3 would be dissociated from Smad2/3 and replaced to HAT, such as p300/CBP (Akiyoshi et al., 1999) . In the experiments presented in Figure 2b , cells were stimulated with TGF-b, so HDACs should be dissociated from Smad2/3 and TSA had no effect on Smad2/3 acetylation.
Enhancement of the transcriptional activity of Smad3 by p300/CBP may be explained in some ways. First, acetylation may stabilize the Smad3 protein. Recently, Gronroos et al. (2002) have shown that the acetylation of Smad7 protects it against ubiquitination and degradation mediated by the ubiquitin ligase Smurf1. As shown in Figure 5a , expression level of K378R mutant is almost same. Moreover, overexpression of p300 or CBP did not affect the expression level of Smad3 as shown in Figure 1a and e. These results suggested that competition between ubiquitination and acetylation of overlapping lysine residues has not occurred in case of Smad3. Secondly, p300/CBP may acetylate and induce a conformational change in Smad3 leading to a decrease in the affinity of Smad3-containing complex with DNA to start the transcription as described previously in the case of Foxo1 (Matsuzaki et al., 2005) . Finally, the acetylation may stimulate the transcriptional activity of Smad3 through the formation of a complex with other transcriptional co-activators. Further study will be required to clarify the last two possibilities.
From the evidence overall, we conclude that p300/ CBP acetylates K378 in the MH2 domain of Smad3 and regulate the transcriptional activity of Smad3. Acetylation of Smad3 may selectively up-or downregulate the expression of TGF-b-regulated genes. Therefore, further study will be required to define the effect of acetylation on the intrinsic activity of Smad3 and biological activity of TGF-b.
Materials and methods
Reagents
Dulbecco's modified Eagle's medium (DMEM) was purchased from Sigma Chemical Co. (St Louis, MO, USA). Fetal bovine serum (FBS) was obtained from HyClone (Logan, UT, USA). Anti-Flag monoclonal antibody (M2), anti-Smad2/3 polyclonal antibody (N-19) , anti-p300 polyclonal antibody (N-15), anti-CBP polyclonal antibody (A-22) and TSA were from Sigma; anti-acetylated-lysine polyclonal antibody was from Cell Signaling Technology (Beverly, MA, USA); anti-HA monoclonal antibody (12CA5) was from Roche (Indianapolis, IN, USA); anti-phospho-Smad2 antibody was from Upstate (Lake Placid, NY, USA) and human recombinant TGF-b 1 was from R&D Systems (Minneapolis, MN, USA).
Plasmids
We used pCMV5/Flag-Smad2, pCMV5/Flag-Smad3 and pCMV5/TbRI(T204D)-HA as described previously (Inoue et al., 2004) . The Smad3 mutants were generated by PCR. The regions amplified by PCR and the presence of missense or deleted mutations were confirmed by sequencing. pCMVb/ p300, pcDNA3/CBP-HA and pcDNA3/CBPHAT(À)-HA were described previously (Kawabata et al., 2002; Takahashi et al., 2002) .
Cell lines and transfections
HepG2 cells and 293 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS, 100 U/ml of penicillin G and 100 mg/ml of streptomycin (Inoue et al., 2004) . The human melanoma cell line A375 was cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 15mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid and 5% heat-inactivated FBS (Inoue et al., 2004) . We transfected cells using the calcium phosphate precipitation method as described previously (Hattori et al., 2003) .
Transcriptional response assay
For transcriptional assays, HepG2 cells were transiently transfected with the reporter plasmid (pFR-Luc, Stratagene, La Jolla, CA, USA), pCMV-b-galactosidase (bgal) or pRL-TK, and the GAL4-Smads construct. After transfection, cells were incubated for 15 h in the absence or presence of 100 pM of TGF-b. Luciferase activity in cell lysates was measured. Luciferase activity was normalized with bgal activity or Renilla luciferase activity.
For the TGF-b-inducible luciferase reporter assay, HepG2 cells were transiently co-transfected with Smad3 expression plasmids and pCMV-bgal in combination with reporter constructs of p3TP-Lux (Carcamo et al., 1994) or pSmad7-Luc (kindly provided by Dr K Miyazono). After transfection, cells were incubated for 15 h in the absence or presence of 100 pM of TGF-b. Luciferase activity in cell lysates was measured. Luciferase activity was normalized with bgal activity.
RT-PCR analysis
Total RNA from 293 cells transfected with Smad3 expression plasmids with pCMV5/TbRI(T204D) was isolated with RNeasy Minikit (Qiagen, Hilden, Germany). One microgram of total RNA were reverse-transcribed with Advantage Smad3 is acetylated to activate by p300/CBP Y Inoue et al RT-for-PCR kit (BD Biosciences, San Jose, CA, USA). Onetenth of the reverse-transcribed materials was used in the PCR reactions. PCR programs and primers used for PCR were as follows: a 941C, 2 min initial denaturation step, 31 cycles (for PAI-1, 5 0 -GTATCTCAGGAAGTCCAGCC-3 0 and 5 0 -TCT AAGGTAGTTGAATCCGAGC-3 0 ), 27 cycles (for Smad7, 5 0 -GCCCTCTCTGGATATCTTCT-3 0 and 5 0 -GCTGCATA AACTCGTGGTCA-3 0 ), 35 cycles (for COL1A2, 5 0 -TCCAAG GACAAGAAACAC-3 0 and 5 0 -GCAGCCATCTACAAGA AC-3 0 ), 25 cycles (for GAPDH, 5 0 -TGAAGGTCGGAGTCA ACGGATTTGGT-3 0 and 5 0 -CATGTGGGCCATGAGGTC CACCAC-3 0 ) at 941C for 15 s, 50-561C for 30 s and 681C for 1 min on a PTC-200 DNA engine thermal cycler (Bio-Rad, Hercules, CA, USA). PCR amplification was performed in the linear range and PCR products were solved by 1.5-2% agarose gel electrophoresis (Enari et al., 2006) .
Immunoprecipitation and Western blot analysis
After transfection with the plasmids, cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate and 1% Triton-X-100) supplemented with protease inhibitors, phosphatase inhibitors and sodium butyrate (10 mM) for inhibiting deacetylase. The lysates were then subjected to immunoprecipitation with anti-Flag M2. Co-immunoprecipitates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), transferred onto polyvinylidine difluoride membranes (Millipore) and probed with the antibody described in the figure legends. The immunoreactive proteins were visualized using enhanced chemiluminescence Western blotting detection reagents (GE Healthcare BioScience, Piscataway, NJ, USA), and the light emission was quantified with a lumino image analyzer LAS-1000 (FUJI).
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BMP, bone morphogenetic protein; DMEM, Dulbecco's modified Eagle's medium; EDTA, ethylenediamine tetraacetic acid; FBS, fetal bovine serum; MH, Mad homology; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; SDS, sodium dodecyl sulfate; TGF-b, transforming growth factor-b.
